Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,461.12 -8.18 (-0.15%) Dow
39,053.60 -58.56 (-0.15%) Nasdaq
17,741.05 +23.40 (+0.13%) Bitcoin USD
61,705.64 -16.48 (-0.03%) CMC Crypto 200
1,278.77 -5.02 (-0.39%)
ITCI Nov 2024 60.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:25PM EDT. Market open.
| Previous close | 15.40 |
| Open | 15.40 |
| Bid | 11.60 |
| Ask | 16.00 |
| Strike | 60.00 |
| Expiry date | 2024-11-15 |
| Day's range | 15.40 - 15.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.